Hepatic hemangioma is the most common benign liver tumor, found in 1-20% of the adult population. It is a hamartomatous lesion composed of blood-filled sinusoidal spaces lined by vascular endothelial cells. Two to five times more common in women and may grow under estrogen influence. Usually discovered incidentally and is asymptomatic. Typical imaging findings — peripheral nodular enhancement, centripetal fill-in, and T2 'light bulb' sign — allow diagnosis without biopsy. Size ranges from <1.5 cm to >20 cm (giant hemangioma).
Age Range
20-70
Peak Age
45
Gender
Female predominant
Prevalence
Very Common
Hepatic hemangioma is a hamartomatous lesion containing enlarged sinusoidal spaces lined by vascular endothelium. These sinusoidal spaces are much wider than normal liver sinusoids and filled with blood — functioning as slow-flow venous pools. Fibrous tissue septa separate the sinusoidal spaces. Contrast enters from the periphery and gradually progresses centripetally due to slow flow — this creates the dynamic 'peripheral nodular enhancement + centripetal fill-in' pattern and is the pathognomonic enhancement characteristic of hemangioma. Slow flow causes contrast to persist in the lesion in delayed phases (persistent enhancement). Marked T2 hyperintensity results from the long T2 relaxation time of static blood in sinusoidal spaces — slow-flowing or stagnant blood behaves like free water. In women, estrogen stimulates endothelial proliferation promoting hemangioma growth; growth may be observed during pregnancy and oral contraceptive use.
Markedly hyperintense (CSF-level) appearance of hemangioma on T2-weighted MRI — called 'light bulb sign' because it is as bright as a light bulb. This signal level results from the long T2 relaxation time of static blood in sinusoidal spaces. Malignant tumors (HCC, metastasis) are much less bright on T2 due to their cellular composition. This difference explains the central role of T2 in hemangioma diagnosis.
Punctate/nodular enhancement foci at lesion periphery in arterial phase — enhances simultaneously and to the same degree as aorta/hepatic artery. No central enhancement (yet). Enhancing nodules appear isodense to aorta (same HU) peripherally. This pattern is also called 'puddle' or 'cotton-wool'.
Report Sentence
Nodular enhancement foci at lesion periphery at the same level as aorta in arterial phase, consistent with hemangioma.
Enhancement progresses from periphery toward center in portal venous phase (centripetal fill-in). Enhanced area enlarges, but center may not yet be completely filled (especially in large lesions). Small hemangiomas (<1.5 cm) may completely fill in this phase. Enhanced areas remain isodense to aorta/vascular structures.
Report Sentence
Enhancement progressing from periphery toward center (centripetal fill-in) in portal venous phase, consistent with hemangioma.
Complete or near-complete enhancement in delayed phase (5-15 min) — lesion becomes isodense or slightly hyperdense to liver parenchyma. NO WASHOUT — this is the most important differentiating point from HCC and metastasis. In giant hemangioma, center may not enhance due to fibrous scar (central hypodensity persists).
Report Sentence
Lesion showing near-complete enhancement with no washout in delayed phase, consistent with hemangioma.
Markedly hyperintense on T2-weighted images ('light bulb' sign). Homogeneous, well-defined. Signal level similar to CSF but slightly lower than simple cyst (simple cyst is brightest). Best evaluated on T2 HASTE or TSE sequences. Mild heterogeneity may be present in giant hemangioma due to central scar.
Report Sentence
Markedly hyperintense lesion on T2-weighted images ('light bulb' sign), consistent with hemangioma.
Homogeneous hyperechoic (brighter than liver parenchyma) lesion on US — most common US appearance. Round/oval, well-defined, may show posterior acoustic enhancement. Size usually <3 cm. Large hemangiomas may be more heterogeneous. In fatty liver (steatosis), hemangioma may appear isoechoic or hypoechoic.
Report Sentence
Homogeneous hyperechoic, well-defined lesion in the liver, consistent with hemangioma.
Hypointense relative to liver parenchyma on T1-weighted images. Homogeneous. Post-gadolinium peripheral nodular enhancement and centripetal fill-in — same dynamic pattern as CT. On hepatobiliary phase (gadoxetic acid) MRI, hemangioma remains hypointense — no uptake.
Report Sentence
Lesion hypointense on T1, showing peripheral nodular enhancement and centripetal fill-in on contrast series, consistent with hemangioma.
Criteria
Size <5 cm. Homogeneous, well-defined. Shows all typical enhancement characteristics. Hyperechoic on US. No follow-up or treatment needed.
Distinct Features
Small (<5 cm), homogeneous, typical enhancement, no follow-up needed
Criteria
Size >5-10 cm. May contain central fibrous scar, thrombus, or calcification. Center may not completely fill in delayed phase. May be symptomatic (pain, compression). Rare complications: Kasabach-Merritt syndrome (DIC), spontaneous rupture.
Distinct Features
Large (>5-10 cm), central scar, heterogeneous, may be symptomatic, Kasabach-Merritt risk
Criteria
Usually <1.5 cm. Completely and homogeneously enhances in arterial phase — does not show classic peripheral nodular pattern. May be confused with HCC or hypervascular metastasis. T2 hyperintensity is distinguishing. No washout in delayed phase (different from HCC).
Distinct Features
Small (<1.5 cm), homogeneous arterial enhancement, T2 hyperintense, no washout
Criteria
Atypical appearance due to fibrosis and hyalinization. Expected bright T2 signal is absent or reduced. Enhancement may be delayed and decreased. May be confused with malignant lesion — biopsy may be needed.
Distinct Features
Atypical, reduced T2 hyperintensity, delayed enhancement, biopsy may be needed
Distinguishing Feature
HCC shows homogeneous arterial enhancement + washout (becoming darker than parenchyma in portal/delayed phase) — hemangioma has peripheral nodular enhancement + fill-in and NO washout. HCC is mildly T2 hyperintense (much lower than marked hyperintensity of hemangioma). HCC expected in cirrhosis/hepatitis background; hemangioma in healthy liver.
Distinguishing Feature
Simple cyst is anechoic with imperceptible wall — hemangioma is hyperechoic and well-defined. No enhancement in simple cyst, peripheral nodular enhancement in hemangioma. Both T2 hyperintense but simple cyst is brighter and more homogeneous. Simple cyst at water density (0 HU) on CT, hemangioma at soft tissue density (30-50 HU).
Distinguishing Feature
FNH shows homogeneous arterial enhancement + isointense/hyperintense in hepatobiliary phase (gadoxetic acid) (contains hepatocytes). Hemangioma remains hypointense in hepatobiliary phase (no hepatocytes). FNH is isointense/mildly T2 hyperintense (central scar T2 hyperintense), hemangioma is markedly T2 hyperintense (light bulb). Central scar enhances in FNH, does not enhance in hemangioma.
Distinguishing Feature
Adenoma shows homogeneous arterial enhancement but no peripheral nodular pattern. Adenoma is isointense/mildly T2 hyperintense (very different from marked hyperintensity of hemangioma). Intralesional fat (opposed-phase signal loss) and hemorrhage (T1 hyperintense) are common in adenoma — these features are absent in hemangioma. Adenoma associated with OCP use in young women.
Urgency
routineManagement
conservativeBiopsy
Not NeededFollow-up
no-follow-upHepatic hemangioma is benign and requires no treatment or follow-up when diagnosed with typical imaging findings. Biopsy is CONTRAINDICATED — high bleeding risk due to vascular structure and low diagnostic yield. Surgical resection or embolization may be considered for symptomatic giant hemangiomas (>10 cm, pain, compression). Kasabach-Merritt syndrome (consumptive coagulopathy) is very rare but life-threatening and requires emergent intervention. Follow-up may be appropriate in women planning pregnancy due to growth risk. In atypical-appearing lesions (T2 hyperintensity absent, atypical enhancement pattern), alternative diagnoses should be evaluated and confirmation with MRI or biopsy should be performed.
Hemangiomas generally require no treatment. Surgery or embolization may be considered for large (>5 cm) or symptomatic lesions. There is no risk of malignant transformation. Biopsy should be avoided due to bleeding risk.